N/A
N=20
Immunological Response After Shrimp Oral Immunotherapy Treatment
Allergy to Shrimp · Immunotherapy
Bottom Line
View on ClinicalTrials.gov: NCT04552522 ↗Enrolled (actual)
20
Serious AEs
25.0%
Results posted
Apr 2026
Primary outcome: Primary: Change in Eliciting Dose of Shrimp During Oral Food Challenge — 3233; 25 mg
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- shrimp allergy with intend to eat shrimp (Other)
- Age
- Pediatric, Adult · 12+ yrs
- Sex
- All
- Sponsor
- Mahidol University
- Primary completion
- Oct 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Eliciting Dose of Shrimp During Oral Food Challenge |
3233; 25 | — |
| SECONDARY Adverse Event From Shrimp Oral Immunotherapy |
— | — |
Summary
Oral immunotherapy is effective in desensitized food allergy. Shrimp allergy is increasing in Thailand. So the purpose of our study is to determine level of specific immunoglobulin E antibodies to shrimp, Immunoglobulin G4 and immunoblot analysis in shrimp allergy patients after shrimp oral immunotherapy.
Eligibility Criteria
Inclusion Criteria
- Age 12 - 40 years old
- History of Immunoglobulin E-mediated shrimp allergy > 3 episode/year or disturb quality of life
- Positive oral food challenge test for shrimp
Exclusion Criteria
- History of shrimp anaphylaxis (include cardiovascular or neurological symptoms)
- Shellfish dependent exercise induced anaphylaxis
- History of cardiovascular disease, uncontrolled asthma, severe atopic dermatitis
- History of Beta-blocker, Angiotensin-converting enzyme inhibitor, Angiotensin receptor blocker, Calcium channel blocker
Data sourced from ClinicalTrials.gov (NCT04552522). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.